Page 114 - EJMO-9-1

Eurasian Journal of Medicine and
Oncology
Genomics of breast cancer in Western Kazakhstan

doi: 10.1038/ng.3374 doi: 10.1038/s41598-020-63759-1
16. Zolk O, Von dem Knesebeck A, Graf N, et al. Cardiovascular 26. Stafford LK, Tang X, Brandt A, et al. Risk of anthracycline-
health status and genetic risk in survivors of childhood induced cardiac dysfunction in adolescent and young adult
neuroblastoma and nephroblastoma treated with (AYA) cancer survivors: Role of genetic susceptibility loci.
doxorubicin: Protocol of the pharmacogenetic part of the Pharmacogenomics J. 2024;24(4):21.
LESS-anthra cross-sectional cohort study. JMIR Res Protoc. doi: 10.1038/s41397-024-00343-0
2022;11(2):e27898.
27. Ni Y, Zbuk KM, Sadler T, et al. ARTICLE germline
doi: 10.2196/27898 mutations and variants in the succinate dehydrogenase
17. Abbasi SA, Baig RM, Ahmed MN, et al. MAP3K1 SNP genes in cowden and cowden-like syndromes. Am J Hum
rs889312 potential risk and MAP3K9 SNP rs11628333 Genet. 2008;83:261-268.
menopause dependent association for breast cancer. Turk J doi: 10.1016/j.ajhg.2008.07.011
Biochem. 2022;47(4):417-423.
28. Liu M, Xie F, Liu M, Zhang Y, Wang S. Association between
doi: 10.1515/tjb-2021-0161 BRCA mutational status and survival in patients with breast
18. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide cancer: A systematic review and meta-analysis. Breast
association study identifies novel breast cancer susceptibility Cancer Res Treat. 2021;186:591-605.
loci. Nature. 2007;447(7148):1087-1093. doi: 10.1007/s10549-021-06104-y
doi: 10.1038/nature05887 29. Geerts D, Cusick JK, Connelly L. The tumor necrosis factor
19. Zheng Q, Ye J, Wu H, Yu Q, Cao J. Association between superfamily: An increasing role in breast cancer. Front
mitogen-activated protein kinase kinase kinase 1 Media SA. 2020;10:622588.
polymorphisms and breast cancer susceptibility: doi: 10.3389/fonc.2020.622588
A meta-analysis of 20 case-control studies. PLoS One.
2014;9(3):e90771. 30. Shah I, Silva-Santisteban A, Germansky KA, et al.
Association between family history and risk of pancreatic
doi: 10.1371/journal.pone.0090771 cancer in patients with BRCA1 and BRCA2 pathogenic
20. Jara L, Gonzalez-Hormazabal P, Cerceno K, et al. Genetic variants. Pancreas. 2022;51(7):733-738.
variants in FGFR2 and MAP3K1 are associated with the risk doi: 10.1097/MPA.0000000000002104
of familial and early-onset breast cancer in a South-American
population. Breast Cancer Res Treat. 2013;137(2):559-569. 31. Anestis A, Zoi I, Papavassiliou AG, Karamouzis MV.
Androgen receptor in breast cancer-clinical and preclinical
doi: 10.1007/s10549-012-2359-z research insights. Molecules. 2020;25(2):358.
21. De Bruin MA, Kwong A, Goldstein BA, et al. Breast cancer doi: 10.3390/molecules25020358
risk factors differ between Asian and white women with
BRCA1/2 mutations. Fam Cancer. 2012;11(3):429-439. 32. Guzman-Arocho YD, Rosenberg SM, Garber JE, et al.
Clinicopathological features and BRCA1 and BRCA2
doi: 10.1007/s10689-012-9531-9 mutation status in a prospective cohort of young women
22. Ramus SJ, Kote-Jarai Z, Friedman LS, et al. Analysis of with breast cancer. Br J Cancer. 2022;126(2):302-309.
BRCA1 and BRCA2 mutations in Hungarian families doi: 10.1038/s41416-021-01597-2
with breast or breast-ovarian cancer. Am J Hum Genet.
1997;60(5):1242-1246. 33. Collins JM, Isaacs C. Management of breast cancer risk in
BRCA1/2 mutation carriers who are unaffected with cancer.
23. Krajc M, Teugels E, Zgajnar J, et al. Five recurrent BRCA1/2 Breast J. 2020;26(8):1520-1527.
mutations are responsible for cancer predisposition in the
majority of Slovenian breast cancer families. BMC Med doi: 10.1111/tbj.13970
Genet. 2008;9:83. 34. Dastgheib SA, Sayad S, Azizi S, et al. Association between
doi: 10.1186/1471-2350-9-83 XRCC2 Arg188His polymorphism and breast cancer
susceptibility: A systematic review and meta-analysis. Asian
24. Bray J, Sludden J, Griffin MJ, et al. Influence of Pac J Cancer Prev. 2024;25(1):43.
pharmacogenetics on response and toxicity in breast cancer
patients treated with doxorubicin and cyclophosphamide. doi: 10.31557/APJCP.2024.25.1.43
Br J Cancer. 2010;102(6):1003-1009. 35. Fu X, Tan W, Song Q, Pei H, Li J. BRCA1 and breast cancer:
Molecular mechanisms and therapeutic strategies. Front Cell
doi: 10.1038/sj.bjc.6605587
Dev Biol. 2022;10:813457.
25. De Talhouet S, Peron J, Vuilleumier A, et al. Clinical outcome
of breast cancer in carriers of BRCA1 and BRCA2 mutations doi: 10.3389/fcell.2022.813457
according to molecular subtypes. Sci Rep. 2020;10(1):7073. 36. Shahbandi A, Nguyen HD, Jackson JG. TP53 mutations and

Volume 9 Issue 1 (2025) 106 doi: 10.36922/ejmo.5385